Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.94
-0.23 (-2.82%)
At close: Mar 9, 2026, 4:00 PM EDT
7.94
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:46 PM EDT
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
528.81M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| Verastem | 30.91M |
| MeiraGTx Holdings | 27.42M |
| Prothena Corporation | 9.68M |
| Ocugen | 4.41M |
| YD Bio | 510.36K |
| Allogene Therapeutics | 22.00K |
FULC News
- 3 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 11 days ago - Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion - Seeking Alpha
- 13 days ago - Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 13 days ago - Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 20 days ago - Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha